Keros Therapeutics’ (KROS) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Keros Therapeutics (NASDAQ:KROS) in a research note issued to investors on Friday morning,Benzinga reports.

Several other analysts also recently weighed in on the company. Jefferies Financial Group assumed coverage on Keros Therapeutics in a research note on Tuesday, November 5th. They set a “buy” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a research report on Thursday, November 7th. Wedbush restated an “outperform” rating and issued a $84.00 target price on shares of Keros Therapeutics in a research note on Thursday, November 7th. Scotiabank started coverage on shares of Keros Therapeutics in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price target on the stock. Finally, Bank of America dropped their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. Twelve investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Keros Therapeutics presently has an average rating of “Buy” and an average price target of $88.89.

Keros Therapeutics Trading Up 3.9 %

Shares of Keros Therapeutics stock opened at $55.92 on Friday. Keros Therapeutics has a 1 year low of $27.31 and a 1 year high of $73.00. The stock has a 50-day moving average price of $59.30 and a 200 day moving average price of $52.17. The company has a market cap of $2.27 billion, a P/E ratio of -10.73 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million during the quarter. During the same period in the previous year, the company earned ($1.33) EPS. The company’s quarterly revenue was up 4750.0% compared to the same quarter last year. On average, equities analysts forecast that Keros Therapeutics will post -5.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Keros Therapeutics

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in shares of Keros Therapeutics by 7.9% during the first quarter. Vanguard Group Inc. now owns 1,545,758 shares of the company’s stock worth $102,329,000 after purchasing an additional 113,563 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in Keros Therapeutics by 14.5% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after acquiring an additional 324 shares in the last quarter. American International Group Inc. lifted its position in shares of Keros Therapeutics by 13.1% during the first quarter. American International Group Inc. now owns 12,653 shares of the company’s stock worth $838,000 after purchasing an additional 1,465 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its stake in shares of Keros Therapeutics by 117.8% during the first quarter. CANADA LIFE ASSURANCE Co now owns 5,217 shares of the company’s stock valued at $345,000 after purchasing an additional 2,822 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Keros Therapeutics by 17.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock valued at $80,666,000 after purchasing an additional 176,803 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.